Cargando…

Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19

OBJECTIVE: To identify whether active use of nonsteroidal antiinflammatory drugs (NSAIDs) increases susceptibility to developing suspected or confirmed coronavirus disease 2019 (COVID‐19) compared to the use of other common analgesics. METHODS: We performed a propensity score–matched cohort study wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandan, Joht Singh, Zemedikun, Dawit Tefra, Thayakaran, Rasiah, Byne, Nathan, Dhalla, Samir, Acosta‐Mena, Dionisio, Gokhale, Krishna M., Thomas, Tom, Sainsbury, Christopher, Subramanian, Anuradhaa, Cooper, Jennifer, Anand, Astha, Okoth, Kelvin O., Wang, Jingya, Adderley, Nicola J., Taverner, Thomas, Denniston, Alastair K., Lord, Janet, Thomas, G. Neil, Buckley, Christopher D., Raza, Karim, Bhala, Neeraj, Nirantharakumar, Krishnarajah, Haroon, Shamil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252419/
https://www.ncbi.nlm.nih.gov/pubmed/33185016
http://dx.doi.org/10.1002/art.41593
_version_ 1783717295782100992
author Chandan, Joht Singh
Zemedikun, Dawit Tefra
Thayakaran, Rasiah
Byne, Nathan
Dhalla, Samir
Acosta‐Mena, Dionisio
Gokhale, Krishna M.
Thomas, Tom
Sainsbury, Christopher
Subramanian, Anuradhaa
Cooper, Jennifer
Anand, Astha
Okoth, Kelvin O.
Wang, Jingya
Adderley, Nicola J.
Taverner, Thomas
Denniston, Alastair K.
Lord, Janet
Thomas, G. Neil
Buckley, Christopher D.
Raza, Karim
Bhala, Neeraj
Nirantharakumar, Krishnarajah
Haroon, Shamil
author_facet Chandan, Joht Singh
Zemedikun, Dawit Tefra
Thayakaran, Rasiah
Byne, Nathan
Dhalla, Samir
Acosta‐Mena, Dionisio
Gokhale, Krishna M.
Thomas, Tom
Sainsbury, Christopher
Subramanian, Anuradhaa
Cooper, Jennifer
Anand, Astha
Okoth, Kelvin O.
Wang, Jingya
Adderley, Nicola J.
Taverner, Thomas
Denniston, Alastair K.
Lord, Janet
Thomas, G. Neil
Buckley, Christopher D.
Raza, Karim
Bhala, Neeraj
Nirantharakumar, Krishnarajah
Haroon, Shamil
author_sort Chandan, Joht Singh
collection PubMed
description OBJECTIVE: To identify whether active use of nonsteroidal antiinflammatory drugs (NSAIDs) increases susceptibility to developing suspected or confirmed coronavirus disease 2019 (COVID‐19) compared to the use of other common analgesics. METHODS: We performed a propensity score–matched cohort study with active comparators, using a large UK primary care data set. The cohort consisted of adult patients age ≥18 years with osteoarthritis (OA) who were followed up from January 30 to July 31, 2020. Patients prescribed an NSAID (excluding topical preparations) were compared to those prescribed either co‐codamol (paracetamol and codeine) or co‐dydramol (paracetamol and dihydrocodeine). A total of 13,202 patients prescribed NSAIDs were identified, compared to 12,457 patients prescribed the comparator drugs. The primary outcome measure was the documentation of suspected or confirmed COVID‐19, and the secondary outcome measure was all‐cause mortality. RESULTS: During follow‐up, the incidence rates of suspected/confirmed COVID‐19 were 15.4 and 19.9 per 1,000 person‐years in the NSAID‐exposed group and comparator group, respectively. Adjusted hazard ratios for suspected or confirmed COVID‐19 among the unmatched and propensity score–matched OA cohorts, using data from clinical consultations in primary care settings, were 0.82 (95% confidence interval [95% CI] 0.62–1.10) and 0.79 (95% CI 0.57–1.11), respectively, and adjusted hazard ratios for the risk of all‐cause mortality were 0.97 (95% CI 0.75–1.27) and 0.85 (95% CI 0.61–1.20), respectively. There was no effect modification by age or sex. CONCLUSION: No increase in the risk of suspected or confirmed COVID‐19 or mortality was observed among patients with OA in a primary care setting who were prescribed NSAIDs as compared to those who received comparator drugs. These results are reassuring and suggest that in the absence of acute illness, NSAIDs can be safely prescribed during the ongoing pandemic.
format Online
Article
Text
id pubmed-8252419
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82524192021-07-07 Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19 Chandan, Joht Singh Zemedikun, Dawit Tefra Thayakaran, Rasiah Byne, Nathan Dhalla, Samir Acosta‐Mena, Dionisio Gokhale, Krishna M. Thomas, Tom Sainsbury, Christopher Subramanian, Anuradhaa Cooper, Jennifer Anand, Astha Okoth, Kelvin O. Wang, Jingya Adderley, Nicola J. Taverner, Thomas Denniston, Alastair K. Lord, Janet Thomas, G. Neil Buckley, Christopher D. Raza, Karim Bhala, Neeraj Nirantharakumar, Krishnarajah Haroon, Shamil Arthritis Rheumatol Covid‐19 OBJECTIVE: To identify whether active use of nonsteroidal antiinflammatory drugs (NSAIDs) increases susceptibility to developing suspected or confirmed coronavirus disease 2019 (COVID‐19) compared to the use of other common analgesics. METHODS: We performed a propensity score–matched cohort study with active comparators, using a large UK primary care data set. The cohort consisted of adult patients age ≥18 years with osteoarthritis (OA) who were followed up from January 30 to July 31, 2020. Patients prescribed an NSAID (excluding topical preparations) were compared to those prescribed either co‐codamol (paracetamol and codeine) or co‐dydramol (paracetamol and dihydrocodeine). A total of 13,202 patients prescribed NSAIDs were identified, compared to 12,457 patients prescribed the comparator drugs. The primary outcome measure was the documentation of suspected or confirmed COVID‐19, and the secondary outcome measure was all‐cause mortality. RESULTS: During follow‐up, the incidence rates of suspected/confirmed COVID‐19 were 15.4 and 19.9 per 1,000 person‐years in the NSAID‐exposed group and comparator group, respectively. Adjusted hazard ratios for suspected or confirmed COVID‐19 among the unmatched and propensity score–matched OA cohorts, using data from clinical consultations in primary care settings, were 0.82 (95% confidence interval [95% CI] 0.62–1.10) and 0.79 (95% CI 0.57–1.11), respectively, and adjusted hazard ratios for the risk of all‐cause mortality were 0.97 (95% CI 0.75–1.27) and 0.85 (95% CI 0.61–1.20), respectively. There was no effect modification by age or sex. CONCLUSION: No increase in the risk of suspected or confirmed COVID‐19 or mortality was observed among patients with OA in a primary care setting who were prescribed NSAIDs as compared to those who received comparator drugs. These results are reassuring and suggest that in the absence of acute illness, NSAIDs can be safely prescribed during the ongoing pandemic. John Wiley and Sons Inc. 2021-04-29 2021-05 /pmc/articles/PMC8252419/ /pubmed/33185016 http://dx.doi.org/10.1002/art.41593 Text en © 2020 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Covid‐19
Chandan, Joht Singh
Zemedikun, Dawit Tefra
Thayakaran, Rasiah
Byne, Nathan
Dhalla, Samir
Acosta‐Mena, Dionisio
Gokhale, Krishna M.
Thomas, Tom
Sainsbury, Christopher
Subramanian, Anuradhaa
Cooper, Jennifer
Anand, Astha
Okoth, Kelvin O.
Wang, Jingya
Adderley, Nicola J.
Taverner, Thomas
Denniston, Alastair K.
Lord, Janet
Thomas, G. Neil
Buckley, Christopher D.
Raza, Karim
Bhala, Neeraj
Nirantharakumar, Krishnarajah
Haroon, Shamil
Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19
title Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19
title_full Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19
title_fullStr Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19
title_full_unstemmed Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19
title_short Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19
title_sort nonsteroidal antiinflammatory drugs and susceptibility to covid‐19
topic Covid‐19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252419/
https://www.ncbi.nlm.nih.gov/pubmed/33185016
http://dx.doi.org/10.1002/art.41593
work_keys_str_mv AT chandanjohtsingh nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT zemedikundawittefra nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT thayakaranrasiah nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT bynenathan nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT dhallasamir nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT acostamenadionisio nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT gokhalekrishnam nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT thomastom nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT sainsburychristopher nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT subramaniananuradhaa nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT cooperjennifer nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT anandastha nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT okothkelvino nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT wangjingya nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT adderleynicolaj nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT tavernerthomas nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT dennistonalastairk nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT lordjanet nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT thomasgneil nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT buckleychristopherd nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT razakarim nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT bhalaneeraj nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT nirantharakumarkrishnarajah nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19
AT haroonshamil nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19